Partnering

Partnering

Autifony will seek strategic partners for disease areas where significant resources are required for the later stages of development and commercialisation.

Autifony is interested in discussing specific in-licensing opportunities at the preclinical or early clinical stages in hearing disorders or in CNS that address significant unmet medical needs, on a case by case basis.

Related News

30May

Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

0 Comments
Stevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
15Apr

Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator

0 Comments
• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of... Read More →
18Jan

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

0 Comments
Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image